Cell and Gene Replacement Strategies for Arginase Deficiency

精氨酸酶缺乏症的细胞和基因替代策略

基本信息

  • 批准号:
    9289701
  • 负责人:
  • 金额:
    $ 34.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-04-01 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The urea cycle is the major pathway for detoxification of ammonia in mammals. Arginase 1 deficiency is thought to be the least common of the urea cycle disorders and results in hyperargininemia. In humans, deficiency of this enzyme is characterized clinically by progressive mental impairment, spasticity, growth retardation, and periodic episodes of hyperammonemia. This proposal is two-fold: 1) to continue to advance gene-based therapies for arginase deficiency utilizing appropriate murine models; viral vectors and genomic correction technology will be applied to examine if animals can be corrected behaviorally and biochemically; and 2) to evaluate an iPSC-derived cell therapy approach with hepatocytes placed on bioactive scaffolds to supply urea cycle function. Preliminary data: Our research group has (amongst other findings): 1) constructed and characterized the arginase 1 knockout mouse; 2) demonstrated long-term survival and rescue with recombinant adeno-associated viral vectors; 3) demonstrated that only low-level ureagenesis is necessary for long-term survival; 4) shown that, using an array of behavioral tests, that treated arginase knockout animals lack nervous system abnormalities and there is no difference in learning or behavior when compared to littermates; 5) shown that peripheral metabolism can result in control of circulating plasma arginine; and 6) loss of arginase gene expression results in abnormalities of intrinsic excitability and the dendritic arbor of neurons. In Aim 1, long-term expression of arginase 2 in muscle by viral vector gene therapy will be performed to examine for biochemical and phenotypic correction in a murine model of arginase deficiency. This approach may avoid neutralizing immune responses in patients with null mutations. In Aim 2, studies will examine if an auxiliary liver grown on scaffolds can supply the minimal urea cycle function necessary to lead to phenotypic correction of hyperargininemia. This approach may be successful for other urea cycle disorders. With successful completion of the proposed studies it is expected that a new therapy with gene and cell replacement will be one step closer for patients afflicted with arginase deficiency.
项目总结/摘要 尿素循环是哺乳动物氨解毒的主要途径。精氨酸酶1缺乏症被认为是 是尿素循环障碍中最不常见的并导致高维生素B2血症。在人类中,缺乏 这种酶的临床特征是进行性精神损伤、痉挛、生长迟缓, 高氨血症的周期性发作这一建议有两个方面:1)继续推进基于基因的 利用适当的鼠模型治疗β-内酰胺酶缺乏症;病毒载体和基因组校正 将应用技术来检查动物是否可以在行为和生化方面得到纠正;以及2) 评估iPSC衍生的细胞治疗方法,将肝细胞置于生物活性支架上以供应尿素 循环函数初步数据:我们的研究小组(在其他发现中):1)构建和 表征了重组蛋白酶1敲除小鼠; 2)证实了重组蛋白酶1的长期存活和拯救。 腺相关病毒载体; 3)证明只有低水平的尿素生成是必要的长期 存活率; 4)使用一系列行为测试表明,经过处理的腺苷酸酶敲除动物缺乏神经紧张, 系统异常,与同窝出生的小鼠相比,在学习或行为方面没有差异; 5)显示 外周代谢可导致循环血浆精氨酸的控制;和6)精氨酸酶基因的丢失 表达导致神经元的内在兴奋性和树突状结构的异常。目标1:长期 将通过病毒载体基因治疗在肌肉中表达精氨酸酶2,以检查生化和 表型校正的小鼠模型中的辅酶A酶缺乏症。这种方法可以避免中和免疫 无效突变患者的反应。在目标2中,研究将检查是否在支架上生长辅助肝脏 可以提供导致高维生素B2血症表型纠正所必需的最小尿素循环功能。这 这种方法对于其他尿素循环障碍可能是成功的。随着拟议研究的顺利完成, 预计一种新的基因和细胞替代疗法将使患有 淀粉酶缺乏。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gerald S Lipshutz其他文献

Gerald S Lipshutz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gerald S Lipshutz', 18)}}的其他基金

Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症的基因治疗临床候选药物开发
  • 批准号:
    10540348
  • 财政年份:
    2022
  • 资助金额:
    $ 34.15万
  • 项目类别:
Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症的基因治疗临床候选药物开发
  • 批准号:
    10339836
  • 财政年份:
    2022
  • 资助金额:
    $ 34.15万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10318637
  • 财政年份:
    2019
  • 资助金额:
    $ 34.15万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    9908195
  • 财政年份:
    2019
  • 资助金额:
    $ 34.15万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10540721
  • 财政年份:
    2019
  • 资助金额:
    $ 34.15万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10080755
  • 财政年份:
    2019
  • 资助金额:
    $ 34.15万
  • 项目类别:
Cell and Gene Replacement Strategies for Arginase Deficiency
精氨酸酶缺乏症的细胞和基因替代策略
  • 批准号:
    10115139
  • 财政年份:
    2017
  • 资助金额:
    $ 34.15万
  • 项目类别:
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症分子治疗的进展
  • 批准号:
    8996735
  • 财政年份:
    2015
  • 资助金额:
    $ 34.15万
  • 项目类别:
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症分子治疗的进展
  • 批准号:
    8872239
  • 财政年份:
    2015
  • 资助金额:
    $ 34.15万
  • 项目类别:
Immunologic Aspects of In Utero or Neonatal AAV-Based Gene Therapy
子宫内或新生儿基于 AAV 的基因治疗的免疫学方面
  • 批准号:
    8915936
  • 财政年份:
    2014
  • 资助金额:
    $ 34.15万
  • 项目类别:

相似海外基金

Enhancing Structural Competency in School-Based Health Centers to Address LGBTQ+ Adolescent Health Equity
增强校本健康中心的结构能力,以解决 LGBTQ 青少年健康公平问题
  • 批准号:
    10608426
  • 财政年份:
    2023
  • 资助金额:
    $ 34.15万
  • 项目类别:
Application and feasability of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care - a pilot study
简短的数字筛查工具的应用和可行性,以解决儿科医疗中父母和青少年烟草和电子烟的使用问题 - 一项试点研究
  • 批准号:
    486580
  • 财政年份:
    2022
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Studentship Programs
Co-design of an intervention to address alcohol use among adolescent boys and young men in Tanzania
共同设计一项干预措施,解决坦桑尼亚青春期男孩和年轻男性的饮酒问题
  • 批准号:
    MR/V032380/1
  • 财政年份:
    2022
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Research Grant
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/1
  • 财政年份:
    2021
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Research Grant
Application of a brief digital screening tool to address parental and adolescent tobacco and electronic cigarette use in pediatric medical care
应用简短的数字筛查工具来解决儿科医疗中父母和青少年烟草和电子烟的使用问题
  • 批准号:
    455984
  • 财政年份:
    2021
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Operating Grants
Complex intervention to optimise adolescent BMI pre-conception to address the double burden of malnutrition: A RCT in rural and urban South Africa
优化青少年孕前体重指数以解决营养不良的双重负担的复杂干预措施:南非农村和城市的随机对照试验
  • 批准号:
    MR/V005790/2
  • 财政年份:
    2021
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Research Grant
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10057761
  • 财政年份:
    2020
  • 资助金额:
    $ 34.15万
  • 项目类别:
Development of the Cannabis Actions and Practices (CAP): A Parent-Focused Intervention to Address Adolescent Marijuana Use
大麻行动和实践 (CAP) 的发展:以家长为中心的干预措施,解决青少年大麻使用问题
  • 批准号:
    10213683
  • 财政年份:
    2020
  • 资助金额:
    $ 34.15万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 34.15万
  • 项目类别:
Designing targeted interventions to address HIV vulnerabilities and improve clinical outcomes among conflict affected adolescent girls and young women under 25 in Northern Uganda
设计有针对性的干预措施,以解决乌干达北部受冲突影响的少女和 25 岁以下年轻妇女的艾滋病毒脆弱性并改善临床结果
  • 批准号:
    356145
  • 财政年份:
    2016
  • 资助金额:
    $ 34.15万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了